But were still not done
GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Ships from United Kingdom 5.0 (14) Ships from United Kingdom 4.5 (128) 4.1 (19) 4.7 (120) 5.0 (114) 5.0 (61) Ships from United Kingdom 5.0 (109) 4.2 (28) Ships from United Kingdom 5.0 (22) Ships from United Kingdom 4.9 (458) 5.0 (149) Ships from United Kingdom 5.0 (5) Ships from United Kingdom 5.0 (7) Ships from United Kingdom 4.7 (120) 5.0 (14) Ships from United Kingdom 5.0 (144) Ships from United Kingdom 4.8 (47) Ships from United Kingdom 5.0 (133) Ships from United Kingdom 4.5 (10) Ships from United Kingdom 3.8 (4) Ships from United Kingdom 4.8 (31) 4.7 (30) 5.0 (115) 4.2 (14) Ships from United Kingdom 5.0 (16) Ships from United Kingdom 5.0 (5) Ships from United Kingdom 5.0 (27) Ships from United Kingdom 5.0 (821) 5.0 (130) Ships from United Kingdom 4.9 (235) Ships from United Kingdom 5.0 (144) Ships from United Kingdom 5.0 (109) 5.0 (53) Ships from United Kingdom 5.0 (14) Ships from United Kingdom 4.2 (77) Ships from United Kingdom 5.0 (80) Ships from United Kingdom 4.9 (18) 5.0 (5) Ships from United Kingdom 5.0 (11) Ships from United Kingdom
They deliver the active ingredient through the skin layers to enter the bloodstream which can potentially work throughout the body
As noted by others (Khan et al., 2020), it remains to be clarified if use of GLP-1 RAs is safe across the HF phenotypes
doi: 10.1515/RNS.2011.044 30 CollingridgeG
